Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

5007 - Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy


30 Sep 2019


Poster Display session 3



Tumour Site


Miren Zuazo


Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253


M. Zuazo1, H. Arasanz2, M.J. García Granda1, A.I. Bocanegra1, G. Fernández-Hinojal2, M. Gato-Cañas3, M. Martínez Aguillo2, B. Hernández Marín2, L. Teijeira2, I. Morilla Ruiz2, R. Vera2, G. Kochan1, D. Escors1

Author affiliations

  • 1 Immunomodulation-oncology, Navarrabiomed, 31008 - Pamplona/ES
  • 2 Medical Oncology, Complejo Hospitalario de Navarra, 31008 - Pamplona/ES
  • 3 Av. De Pío Xii, 55, Centro de Investigación Médica Aplicada, Pamplona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 5007


The majority of advanced non-small cell lung cancer (NSCLC) patients who receive PD-L1/PD-1 blockade immunotherapy as a second-line treatment do not respond. These treatments might not only affect the tumor microenvironment, but also alters the systemic dynamics of immune cell populations. Thus, the role of CD4 immunity in patients undergoing PD-L1/PD-1 blockade therapy remains unclear.


Peripheral blood samples from 51 NSCLC patients were obtained previous to the initiation of the PD-L1/PD-1 blockade therapy. Baseline T cell differentiation subsets based on CD27/CD28 expression were quantified by flow cytometry and correlated with responses. Baseline CD4 and CD8 T cells from NSCLC patients were co-cultured with T cell-stimulator cell line by expressing a membrane-bound anti-CD3 single-chain antibody in A549 human lung adenocarcinoma cells line (A549-SC3 cells) and PD-1, LAG-3 and Ki67 markers were assessed by flow cytometry.


In our cohort study NSCLC patients were separated in two groups by a cut-off value of 40% CD4 THD (CD27-CD28low/-) cells: “G1 cohort” patients with more than 40% THD cells, and “G2 cohort” patients with less than 40%. Objective responders were found only within the G1 cohort (P = 0.0001). Interestingly, CD4 T cells from G2 patients were remarkably impaired in proliferation after ex vivo activation with A549-SC3 cells compared to CD4 T cells from G1 patients. CD8 T cells from both G1 and G2 patients were equally impaired in proliferation. CD4 T cells from G2 donors presented a significantly higher co-expression of PD-1 and LAG-3 compared with CD4 T cell from G1 donors after stimulation. CD4 T cells from both G1 and G2 patient cohorts were proficient in cytokine expression. Moreover, the proliferative capacities of CD8 T cells were recovered during after immunotherapy but only in patients with functional proliferative CD4 immunity.


This study uncovers that proliferative functionality of systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy. Moreover, CD4 T cells from G2 patients were not exhausted, indeed they responded to stimulation by producing cytokines although with strong co-upregulation of PD-1/LAG-3 associated with diminished proliferative capacities.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Immunomodulation group-Navarrabiomed Research Center.


Asociación Española Contra el Cáncer (AECC).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.